Abzena - FY18 results – clouds lifting
Following a stronger H2 and Abzena’s FY18 results, we have made major changes to our model across both the services business and the Abzena Inside...
123 Views
Abzena - Starting to get back on track
In its interim results for the year-ending March 2018, Abzena started to move out from under the shadow of September’s disappointing trading...
130 Views
Disappointing trading update but outlook positive
Abzena announced a disappointing business update, indicating revenues for each of its service lines have been below expectations. This has an...
142 Views
Continuing to secure deals that validate model
Abzena has announced another licensing deal, this time involving its Composite Human Antibody technology. The deal is with Telix Pharmaceuticals, a...
147 Views
Another licence agreement that validates model
Abzena has announced another licensing deal for its proprietary site-specific ThioBridge antibody drug conjugate (ADC) linker technology. This time...
145 Views
No more insights